Matheson LLP's international focus and commitment to the life sciences sector has brought it a wealth of top clients in the pharmaceutical and medtech sectors, leading to a steady pipeline of transactional, corporate advisory and regulatory advisory instructions. It has continued to work on some of the highest value cross-border transactions in the sector The firm is also a healthcare litigation heavyweight, especially medical malpractice and product liability litigation, while also having a strong presence in healthcare transactions, including a number of recent hospital and nursing home deals. Litigator Rebecca Ryan is a leader in healthcare, disease and product liability cases. Kate McKenna is a key figure for life sciences regulatory matters, while David Fitzgibbon is at the forefront of life sciences M&A, along with John Coary. Emma Doherty specialises in corporate governance for both healthcare and life sciences businesses.
Legal 500 redaktioneller Kommentar
- Profil
- Soziale Medien
Kernmandanten
- Aerogen
- Agilent Technologies
- Arena Pharmaceuticals
- Astrix Technology
- BioIQ
- Bon Secours Mercy Health
- Centrient Pharmaceuticals
- Chemocentryx
- Ethypharm SAS
- Grifols
Highlight-Mandate
- Advised on all aspects of the proposed acquisition of Horizon Therapeutics by Pillartree.
- Advised Macquarie Asset Management in relation to its agreement to acquire the Beacon Hospital Group.
- Advised Medlab and Sonic Healthcare Ireland, and their insurers, in relation to a number of complex and high value negligence actions arising from Cervical Check screening.
Anwält*innen
Führende Partner*innen
Die stärksten Partner*innen ihres Praxisbereichs, die eine führende Rolle in signifikanten Mandaten einnehmen und weitreichende Anerkennung unter Wettbewerbern und Mandanten genießen.
Praxisleitung
Rebecca Ryan; Emma Doherty; Kate McKenna
Weitere Kernanwält*innen
David Fitzgibbon; John Coary